Immunotherapy combined with chemotherapy has been established as the standard first-line treatment in advanced esophageal cancer (EC). Myelosuppression is the most common side effects of chemotherapy, and severe myelosuppression often leads to prolonged cycles of chemotherapy and reduced doses of chemotherapy, thereby reducing the intensity and potential anti-tumor efficacy of chemotherapy. At present, granulocyte-stimulating factor (G-CSF) is widely used to stimulate the differentiation of bone marrow hematopoietic progenitor cells to treat chemotherapy-induced myelosuppression (CIM). Trilaciclib is a short-acting and reversible CDK4/6 inhibitor, which can provide systemic protection of bone marrow hematopoiesis, and was approved by NMPA in July 2022 for the prophylactic treatment of myelosuppression in extensive-stage small cell lung cancer (ES-SCLC). However, trilaciclib has not been widely used in clinical practice. Therefore, this paper reports a case of one patient with advanced EC who was treated by trilaciclib to prevent CIM in our department, aiming to provide further reference and basis for further investigation.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |